STERILE GOODS MANAGEMENT Sterile Reprocessing Expert Training
SQ.line Ergonomically designed instruments
Health care professionals Take care of your skin
#wearebusy because our customers are
help to slow the spread of covid-19
Choose a category or subcategory
CAPS® Hosts Ribbon Cutting Ceremony for State-of-the Art 503B Outsourcing Facility in Phoenix, AZ
Central Admixture Pharmacy Services, Inc. (CAPS), a B. Braun company and the nation’s largest network of outsourcing admixture pharmacies, held a ribbon cutting ceremony today for its new sterile compounding outsourcing facility in Phoenix, AZ, bringing nearly 400 jobs to the area. U.S. Representative Ruben Gallego, from Arizona’s 7th Congressional District, was on hand to cut the ribbon and make remarks. “I want to welcome CAPS to Arizona’s 7th district. Their investment in our community will not only bring new jobs and training opportunities for Arizonans, but they will also help distribute necessary medicines to improve health outcomes for patients in our state and across the country,” said Gallego, “Businesses like CAPS are helping each day to make our community a better place to live, work, and raise a family.”
B. Braun Announces $1 Billion Investment to Alleviate IV Fluid Shortages in the U.S. Healthcare System
Solutions for Life represents B. Braun’s commitment to expand capacity and help ensure supply of life-saving fluids for hospitals, outpatient settings, and other care institutions.
B. Braun Accelerator enters the second round
With the launch of the B. Braun Accelerator in 2017, the company intensified its cooperation with start-ups and supported product innovations to develop new technologies and business models in the Home Care division. On Wednesday, the B. Braun Accelerator entered the second round with a kickoff workshop and a newly developed collaboration program in Melsungen.
2018 fiscal year: B. Braun increases sales and invests over 1.2 billion euros
Melsungen. B. Braun Melsungen AG completed the fiscal year 2018 with total sales of € 6,908 million (previous year: € 6,789 million). Sales increased from the previous year by 1.8 percent (currency-adjusted, +5.3 percent). EBITDA fell 3.3 percent from the previous year with € 952.5 million.